tirzepatide surmount 2 surmount-1 trial obesity without diabetes weight loss non-diabetic once weekly for the treatment of in people with type ( SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 SURMOUNT-1: Tirzepatide Drastically The Story of Mounjaro (Tirzepatide)

For patients with obesity-related comorbidities such as hypertension, dyslipidaemia, or fatty liver disease these combined effects could represent a clinically meaningful advance if confirmed in Phase 3 data

Having overweight or obesity can affect your hormone levels, which can cause missed periods or, in other cases, heavy menstrual bleeding

Call us today to see if weight loss injections are right for you

Prioritise sleep hygiene: Implementing good sleep practices can help reduce fatigue and improve overall tolerance to the medication

Emerging observational evidence indicates cardiovascular benefits from extended rather than reduced eating windows and increased mortality risk associated with long-term application of TRE